follow us
The recent $13 billion acquisition of Interpublic Group by Omnicom Group, which creates the largest advertising entity globally, has sparked significant debate, particularly involving Federal Trade Commission (FTC) Chairman Andrew Ferguson and former President Donald Trump. During a meeting in the Oval Office last August, Trump invited Chris Ruddy, CEO of Newsmax, to discuss the deal, which was initially expected to be a routine review by FTC staff. Ruddy, who had been advocating for the deal's blockage, claimed he was a victim of an advertising boycott and alleged that Ferguson had not responded to his communications.
During the call, Trump encouraged Ruddy to present his case against the merger. Ruddy proposed that if the deal were approved, the merging companies should contribute $250 million to a fund for those affected by the boycott. Trump reportedly dismissed this request, labeling it as “bullshit.” Ultimately, Ferguson allowed the acquisition to proceed, despite Ruddy's objections. A spokesperson for Newsmax later contested the portrayal of the call, including the claim regarding the $250 million request.
Trump's involvement in regulatory matters marks a notable shift in the traditional separation of powers between the presidency and independent agencies. Historically, presidents have refrained from influencing agency decisions, allowing them to operate autonomously. However, Trump's administration has seen a significant increase in direct presidential engagement with regulatory processes, with lobbying efforts targeting the White House rising by 70% in 2025, according to federal filings.
Current agency heads, such as Brendan Carr of the Federal Communications Commission (FCC), have expressed support for Trump's direct involvement, suggesting that it helps shape discussions and decisions. This approach has led to a more politicized environment within federal agencies, with critics arguing that the expertise of these bodies is being leveraged for political ends. Trump's administration has also seen the dismissal of officials who do not align with his agenda, exemplified by the ousting of FDA Commissioner Marty Makary.
As the 2024 election approaches, the implications of Trump's regulatory strategy are becoming increasingly apparent. The FTC, under Ferguson, has adopted a more aggressive stance, as seen in its handling of antitrust cases involving major corporations like Meta. This shift has raised concerns among former officials about the integrity of the agency and its ability to operate independently. The evolving landscape of federal regulatory oversight under Trump continues to draw scrutiny, as the balance of power between the presidency and independent agencies undergoes significant transformation.
